Your browser doesn't support javascript.
loading
Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis.
Smith, Stephen D; Lopedote, Paolo; Samara, Yazeed; Mei, Matthew; Herrera, Alex F; Winter, Allison M; Hill, Brian T; Shadman, Mazyar; Ujjani, Chaitra; Lynch, Ryan C; Jacobson, Caron A; Kim, Austin I; Caimi, Paolo; Milano, Filippo; Gopal, Ajay K.
Afiliación
  • Smith SD; Division of Medical Oncology, Department of Internal Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address: Ssmith50@seattlecca.org.
  • Lopedote P; Institute of Hematology, University of Bologna, Bologna, Italy.
  • Samara Y; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
  • Mei M; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
  • Herrera AF; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
  • Winter AM; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH.
  • Hill BT; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH.
  • Shadman M; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Ujjani C; Division of Medical Oncology, Department of Internal Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Lynch RC; Division of Medical Oncology, Department of Internal Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Jacobson CA; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA.
  • Kim AI; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA.
  • Caimi P; Department of Medicine-Hematology and Oncology, University Hospital/Case Western Reserve Medical Center, Cleveland, OH.
  • Milano F; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Gopal AK; Division of Medical Oncology, Department of Internal Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Clin Lymphoma Myeloma Leuk ; 21(3): 170-175, 2021 03.
Article en En | MEDLINE | ID: mdl-33431309
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B / Inmunoconjugados / Antineoplásicos Inmunológicos / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Lymphoma Myeloma Leuk Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B / Inmunoconjugados / Antineoplásicos Inmunológicos / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Lymphoma Myeloma Leuk Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos